Your browser doesn't support javascript.
loading
Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer.
Mayo, Zachary S; Ilori, Evelyn O; Matia, Brian; Smile, Timothy D; Fleming, Christopher W; Reddy, Chandana A; Scharpf, Joseph; Lamarre, Eric D; Prendes, Brandon L; Ku, Jamie; Burkey, Brian B; Joshi, Nikhil P; Woody, Neil M; Koyfman, Shlomo A; Campbell, Shauna R.
Afiliación
  • Mayo ZS; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Ilori EO; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Matia B; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Smile TD; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Fleming CW; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Reddy CA; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Scharpf J; Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
  • Lamarre ED; Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
  • Prendes BL; Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
  • Ku J; Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
  • Burkey BB; Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
  • Joshi NP; Rush University Medical Center, Department of Radiation Oncology, Chicago, IL, U.S.A.
  • Woody NM; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Koyfman SA; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
  • Campbell SR; Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.; campbes6@ccf.org.
Anticancer Res ; 42(4): 1845-1849, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35347002
BACKGROUND/AIM: Hypofractionated radiation therapy is not commonly used in head and neck cancers (HNC) due to increased toxicity observed in historical cohorts. This study reviews our institutional experience using hypofractionated intensity modulated radiation therapy (H-IMRT) for HNC. PATIENTS AND METHODS: A retrospective cohort study of 56 patients with HNC treated with H-IMRT with ≥50 Gy in 20 fractions was conducted. The primary outcomes were acute and late toxicity. RESULTS: Two-year locoregional control was 87% and median overall survival was 46 months. There were no acute or late grade 4 or 5 toxicities. Acute grade 2 and 3 toxicity was seen in 79% (N=44) and 25% (N=14), respectively. Late grade 2 toxicity was seen in 9% (N=5). No patients required the placement of a feeding tube or tracheostomy. CONCLUSION: H-IMRT for the definitive or post-operative treatment of HNC using ≥50 Gy in 20 fractions appears safe and well tolerated with modest toxicity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioterapia de Intensidad Modulada / Neoplasias de Cabeza y Cuello Tipo de estudio: Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioterapia de Intensidad Modulada / Neoplasias de Cabeza y Cuello Tipo de estudio: Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Grecia